Advanced Biomed Inc. 8-K

What Happened
Advanced Biomed Inc. announced on April 2, 2026 that it entered into a Share Purchase Agreement to acquire 100% of Acellent Technologies (Hong Kong) Co. Limited, a Hong Kong company that provides AI-powered financial verification and audit solutions. The purchase price is 270,000 shares of Advanced Biomed common stock (par value $0.001), which the company estimates at $4.00 per share for an aggregate estimated value of $1,080,000. The agreement is between Advanced Biomed, the Target, and the Target’s sole shareholder (listed in the agreement as Xiaomin Chen). Closing is conditioned on completion of financial and legal due diligence and receipt of any required regulatory approvals. The full agreement is filed as Exhibit 10.1 to the 8-K.

Key Details

• Agreement date: April 2, 2026.
• Target: Acellent Technologies (Hong Kong) Co. Limited — AI-powered financial verification and audit solutions.
• Consideration: 270,000 shares of Advanced Biomed common stock; estimated value $4.00 per share; aggregate estimated value $1,080,000.
• Closing conditions: completion of financial and legal due diligence and required regulatory approvals.
• Agreement filed as Exhibit 10.1 to the Form 8-K.

Why It Matters
This is a stock‑based acquisition that, if completed, will transfer ownership of Acellent to Advanced Biomed in exchange for 270,000 shares of common stock — a non-cash transaction that will increase the company’s outstanding shares if issued. The deal brings AI-driven financial verification and audit capabilities into Advanced Biomed’s perimeter, which could broaden the company’s business scope beyond its current operations. Investors should note the transaction is not yet closed and depends on due diligence and regulatory approvals; watch for subsequent filings confirming closing, share issuance details, or any material changes.